Business
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":" ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.\n\n\nAurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Tuesday, April 16, from 10:30 to 11:00 AM Eastern Time. A live webcast of the session will be available on the Investor section of Aurinia’s website, which can be found here.\n\n\nAbout Aurinia\nAurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240409722071/en/\n\nMedia and Investor Inquiries:\nAndrea Christopher\nCorporate Communications and Investor Relations, Aurinia\[email protected]\[email protected]\n\n\nSource: Aurinia Pharmaceuticals Inc.","length":2990,"tagName":"div"}]